Real-world effectiveness of Ruxolitinib: analysis and comparison with COMFORT-II

The analysis included 466 patients with myelofibrosis on treatment with ruxolitinib. The PFS at 12 th , 20 th , 30 th , 40 th , and 50 th month was 88%, 83%, 75%, 65%, and 61% respectively. Median for PFS was reached at 73.5 months. OS median was reached at 48.2 months. OS at month 12 th , 20 th , 30 th , and 40 th month was 87%, 78%, 70%, and 56% respectively. Eligible patients for comparison with COMFORT-II trial after application of inclusion and exclusion criteria were 68, while the clinical trial included 146 patients. The estimated value for PFS at 12 th month was 84% and the median PFS was reached at 35.3 months. The values for OS was estimated to be 74% at 12 th month and the median of OS was reached at 30 th month. The clinical benefit rate from real-world population was estimated at 98%, and objective response rate was estimated at 79.2%, based on 53 patients.